PNP Therapeutics®, Inc. is a clinical-stage, biopharmaceutical company engaged in the development of a platform technology (Gedeptin®) and proprietary products for the treatment of cancer. Learn more about PNP Therapeutics >.
On September 28, 2021, PNP entered into an Assignment and License Agreement with GeoVax, Inc., whereby GeoVax obtained an exclusive license to PNP’s intellectual property and related assets associated with Gedeptin®. All inquiries concerning Gedeptin® should now be directed to GeoVax.
News & Events
September 28, 2021 > - PNP Therapeutics Licenses IP and Related Assets to GeoVax
June 16, 2015 > - PNP Therapeutics Inc. Receives Orphan Drug Status for Gedeptin
November 21, 2013 > PNP Therapeutics Cancer-fighting Technology Progressing Well in Phase I Clinical Trial